Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Gisbert

Showing results (181-190 of 211) with videos related to

Pageof 22
Sort By:
Human Immunology|October 15, 2013
Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximabL M Medrano, C Taxonera, A Márquez, et al.
Alimentary Pharmacology & Therapeutics|December 8, 2010
Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximabC Taxonera, J Estellés, I Fernández-Blanco, et al.
Alimentary Pharmacology & Therapeutics|November 25, 2015
Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis GroupF Fernández-Bañares, M J Casanova, Y Arguedas, et al.
Revista Espanola De Enfermedades Digestivas|July 3, 2004
Predictors of response to infliximab in patients with fistulizing Crohn's diseaseM Luna-Chadid, J L Pérez Calle, J L Mendoza, et al.
Alimentary Pharmacology & Therapeutics|December 7, 2011
Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre studyM Chaparro, P Burgueño, E Iglesias, et al.
Journal of Crohn'S & Colitis|September 11, 2013
Disease severity in familial cases of IBDM Andreu, L Márquez, E Domènech, et al.
Biochemical Pharmacology|September 25, 2016
Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximabB Hernández-Breijo, M Chaparro, D Cano-Martínez, et al.
Digestive Diseases and Sciences|September 13, 2013
Health care costs of complex perianal fistula in Crohn's diseaseM Chaparro, C Zanotti, P Burgueño, et al.
Mucosal Immunology|May 11, 2018
Human intestinal pro-inflammatory CD11c<sup>high</sup>CCR2<sup>+</sup>CX3CR1<sup>+</sup> macrophages, but not their tolerogenic CD11c<sup>-</sup>CCR2<sup>-</sup>CX3CR1<sup>-</sup> counterparts, are expanded in inflammatory bowel diseaseD Bernardo, A C Marin, S Fernández-Tomé, et al.
Alimentary Pharmacology & Therapeutics|March 18, 2015
Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON studyJ Molina-Infante, A J Lucendo, T Angueira, et al.
Pageof 22

Showing results (181-190 of 211) with videos related to

Sort By:
Pageof 22
Human Immunology|October 15, 2013
Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximabL M Medrano, C Taxonera, A Márquez, et al.
Alimentary Pharmacology & Therapeutics|December 8, 2010
Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximabC Taxonera, J Estellés, I Fernández-Blanco, et al.
Alimentary Pharmacology & Therapeutics|November 25, 2015
Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis GroupF Fernández-Bañares, M J Casanova, Y Arguedas, et al.
Revista Espanola De Enfermedades Digestivas|July 3, 2004
Predictors of response to infliximab in patients with fistulizing Crohn's diseaseM Luna-Chadid, J L Pérez Calle, J L Mendoza, et al.
Alimentary Pharmacology & Therapeutics|December 7, 2011
Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre studyM Chaparro, P Burgueño, E Iglesias, et al.
Journal of Crohn'S & Colitis|September 11, 2013
Disease severity in familial cases of IBDM Andreu, L Márquez, E Domènech, et al.
Biochemical Pharmacology|September 25, 2016
Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximabB Hernández-Breijo, M Chaparro, D Cano-Martínez, et al.
Digestive Diseases and Sciences|September 13, 2013
Health care costs of complex perianal fistula in Crohn's diseaseM Chaparro, C Zanotti, P Burgueño, et al.
Mucosal Immunology|May 11, 2018
Human intestinal pro-inflammatory CD11c<sup>high</sup>CCR2<sup>+</sup>CX3CR1<sup>+</sup> macrophages, but not their tolerogenic CD11c<sup>-</sup>CCR2<sup>-</sup>CX3CR1<sup>-</sup> counterparts, are expanded in inflammatory bowel diseaseD Bernardo, A C Marin, S Fernández-Tomé, et al.
Alimentary Pharmacology & Therapeutics|March 18, 2015
Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON studyJ Molina-Infante, A J Lucendo, T Angueira, et al.
Pageof 22